Tilray Surges After Privateer Holdings Vows to Hold Stake Until At Least H2 2019
https://www.thestreet.com/investing/sto ... 9-14831335
Tilray Brands, Inc. NASDAQ: TLRY produkcja medycznej marihuany
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray Boosts Production Capacity With $26.3 Million Purchase of Natura Naturals
https://www.thestreet.com/investing/can ... s-14840898
https://www.thestreet.com/investing/can ... s-14840898
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
How Tilray Can Pass Its First Major Test of 2019
It's a critical time for Canadian cannabis company Tilray (TLRY) as the revenue projections for the company begin to ramp at ever steeper levels as the market for its product matures internationally.
The company is scheduled to report fourth-quarter results after the closing bell on Monday, March 18, and the expectations are for the company to report a 58% sequential jump in revenue.
Analysts expect Tilray to report revenue of $15.86 million and a loss of 15 cents per share. In the previous quarter, the reported revenue of $10.05 million and loss of 20 cents.
But that is only the beginning.
Tilray is expected to more than double revenue in the first quarter 2019 from the fourth quarter 2018. For fiscal 2019, Tilray is expected to increase revenue 350% from fiscal 2018.
That expected increase in revenue is tied to its purchase of fellow Canadian cannabis producer Natura Naturals for $26.3 million in late 2018. Tilray purchased Manitoba Harvest for $317 million in February, but the benefits from that purchase aren't expected to be reflected in Tilray's operations until it reports its first-quarter numbers.
Tilray recently was initiated at Jefferies with an underperform rating and initiated at Piper Jaffray at overweight.
Tilray shares have declined 4% year to date. The stock was up 0.7% Friday.
https://www.thestreet.com/investing/can ... 9-14897651
It's a critical time for Canadian cannabis company Tilray (TLRY) as the revenue projections for the company begin to ramp at ever steeper levels as the market for its product matures internationally.
The company is scheduled to report fourth-quarter results after the closing bell on Monday, March 18, and the expectations are for the company to report a 58% sequential jump in revenue.
Analysts expect Tilray to report revenue of $15.86 million and a loss of 15 cents per share. In the previous quarter, the reported revenue of $10.05 million and loss of 20 cents.
But that is only the beginning.
Tilray is expected to more than double revenue in the first quarter 2019 from the fourth quarter 2018. For fiscal 2019, Tilray is expected to increase revenue 350% from fiscal 2018.
That expected increase in revenue is tied to its purchase of fellow Canadian cannabis producer Natura Naturals for $26.3 million in late 2018. Tilray purchased Manitoba Harvest for $317 million in February, but the benefits from that purchase aren't expected to be reflected in Tilray's operations until it reports its first-quarter numbers.
Tilray recently was initiated at Jefferies with an underperform rating and initiated at Piper Jaffray at overweight.
Tilray shares have declined 4% year to date. The stock was up 0.7% Friday.
https://www.thestreet.com/investing/can ... 9-14897651
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray To Focus More On U.S., Europe, Tilray Stock Jumps On Earnings
https://www.investors.com/news/marijuan ... ray-stock/
https://www.investors.com/news/marijuan ... ray-stock/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Jeden z największych producentów marihuany - kanadyjski Tilray (TLRY) ogłosił wyniki za czwarty kwartał i cały rok 2019 po zamknięciu notowań w poniedziałek. Firma osiągnęła przychody w wysokości 46,9 mln USD w czwartym kwartale, co stanowi wzrost o 202% r/r. Przychody za cały rok 2020 wyniosły prawie 167 mln USD, co stanowi wzrost o 287% w porównaniu z rokiem poprzednim. Jednak spółka nadal wydaje więcej niż zarabia - producent odnotował stratę netto w czwartym kwartale w wysokości 219,1 mln USD, czyli 2,14 USD na akcję. Strata netto za cały rok 2020 wyniosła 321,1 mln USD, czyli 3,20 USD na akcję. Bilans jest dowodem na to, że przed Tilray stoi szereg wyzwań, a doniczkowa branża jeszcze długo pozostanie nierentowna.
Legalizacja marihuany w Ameryce Północnej robi postępy - 11 stanów plus Waszyngton, w ciągu ostatnich kilku lat, zalegalizowało marihuanę rekreacyjną. Kanada zezwoliła na pełną legalizację w październiku 2018 r.
...
https://www.paszport.ws/szalony-poniedz ... -od-11-lat
Legalizacja marihuany w Ameryce Północnej robi postępy - 11 stanów plus Waszyngton, w ciągu ostatnich kilku lat, zalegalizowało marihuanę rekreacyjną. Kanada zezwoliła na pełną legalizację w październiku 2018 r.
...
https://www.paszport.ws/szalony-poniedz ... -od-11-lat
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Why Tilray Stock Is Soaring Again After a Terrible Year
A month ago, Canada-based cannabis company Tilray Inc. (NASDAQ: TLRY) closed at $16.57 a share. On March 25, shares closed at $5.04. In the early afternoon on March 26, the stock traded at around $8.39, up about 67% for the day.
On March 13, the company announced an underwritten secondary offering of 7,250,000 shares of its Class 2 common stock, along with warrants to purchase 11,750,000 of its Class 2 common shares and accompanying warrants to purchase another 19,000,000 Class 2 shares. The stock closed at $4.03 on its way to a 52-week low of $2.43 a few days later.
Aside from a dreadful fourth-quarter earnings report, there is no other company-reported information since the beginning of the year.
Something is moving Tilray stock far higher than other pot stocks. Other Canadian cannabis companies posted solid gains Thursday as well. Aurora Cannabis Inc. (NYSE: ACB) traded up more than 24% and Aphria Inc. (NYSE: APHA) traded more than 17% higher. Cronos Group Inc. (NASDAQ: CRON) traded up nearly 16%m and Canopy Growth Corp. (NYSE: CGC) was up more than 12%.
Medical Cannabis Is Paving the Way
On a fundamental level, all these pot sellers benefit from being able to remain open as “essential” businesses during the shutdown of most businesses, except grocery stores and gas stations, due to the coronavirus outbreaks in Canada and the United States. That exemption means that pot growers that were hammered last year might be able to meet sharply lowered expectations this year.
Tilray shares dropped nearly 76% in 2019, Canopy Growth dumped 27%, Cronos fell by more than 32% and Aurora Cannabis lost nearly 59% of its value. The carnage began to slow earlier this month and turned higher last week when it became clear that cannabis retail stores would be able to remain open during the shutdown.
Retail pot sellers have adopted curbside pickup and, where the law allows, home delivery to try to keep sales up. Prices have dropped and, of course, there are customers who are buying all they can afford, just in case.
Still, all that doesn’t begin to account for a 67% one-day jump in Tilray’s share price.
...
https://247wallst.com/consumer-products ... ible-year/
A month ago, Canada-based cannabis company Tilray Inc. (NASDAQ: TLRY) closed at $16.57 a share. On March 25, shares closed at $5.04. In the early afternoon on March 26, the stock traded at around $8.39, up about 67% for the day.
On March 13, the company announced an underwritten secondary offering of 7,250,000 shares of its Class 2 common stock, along with warrants to purchase 11,750,000 of its Class 2 common shares and accompanying warrants to purchase another 19,000,000 Class 2 shares. The stock closed at $4.03 on its way to a 52-week low of $2.43 a few days later.
Aside from a dreadful fourth-quarter earnings report, there is no other company-reported information since the beginning of the year.
Something is moving Tilray stock far higher than other pot stocks. Other Canadian cannabis companies posted solid gains Thursday as well. Aurora Cannabis Inc. (NYSE: ACB) traded up more than 24% and Aphria Inc. (NYSE: APHA) traded more than 17% higher. Cronos Group Inc. (NASDAQ: CRON) traded up nearly 16%m and Canopy Growth Corp. (NYSE: CGC) was up more than 12%.
Medical Cannabis Is Paving the Way
On a fundamental level, all these pot sellers benefit from being able to remain open as “essential” businesses during the shutdown of most businesses, except grocery stores and gas stations, due to the coronavirus outbreaks in Canada and the United States. That exemption means that pot growers that were hammered last year might be able to meet sharply lowered expectations this year.
Tilray shares dropped nearly 76% in 2019, Canopy Growth dumped 27%, Cronos fell by more than 32% and Aurora Cannabis lost nearly 59% of its value. The carnage began to slow earlier this month and turned higher last week when it became clear that cannabis retail stores would be able to remain open during the shutdown.
Retail pot sellers have adopted curbside pickup and, where the law allows, home delivery to try to keep sales up. Prices have dropped and, of course, there are customers who are buying all they can afford, just in case.
Still, all that doesn’t begin to account for a 67% one-day jump in Tilray’s share price.
...
https://247wallst.com/consumer-products ... ible-year/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Why to Keep an Eye on Tilray Stock?
The stress of quarantine lockdown may be enough to drive a person to drink or drugs. Scientists are just starting to study whether drug use has gone up during the coronavirus pandemic.
So it’s too soon to tell what impact COVID-19 will have on legal and medical cannabis companies such as Canada’s Tilray Inc. (NASDAQ: TLRY). But analysts will be watching the company’s next earnings report, due May 11, for clues. Most expect marijuana stocks to remain volatile in the near term.
Tilray stock was up 5.23% in the last month, but is down over 57% year to date. This downward trend has attracted short sellers. And access to cash remains a concern.
Legalization Trends
As more U.S. states and foreign countries move to legalize recreational or medical cannabis products, legal investment options will grow. But nascent industries come with volatility. Tilray’s 52-week range spans from $2.43 to $51.03, with the stock currently trading in the $7 to $8 range.
Observers are closely watching the Canadian cannabis experiment. The country legalized recreational use in October 2018. Uruguay is the only other country to legalize the sale of recreational pot so far, though a few others have legalized its use.
Some cannabis industry executives actually think the current economic crisis could benefit them in the long run. They point out that alcohol prohibition ended quickly after the Great Depression, as the federal government badly needed revenue and job growth. Legalized marijuana taxes could be a tempting proposition for states (and maybe even Washington?) staring at empty coffers.
On the flip side, legalization efforts may be stymied by legislatures overwhelmed with other priorities. Grassroots efforts requiring the mass collection of voter signatures obviously face an uphill battle in the age of social distancing.
Recreational marijuana is currently legal in 11 states. A few other jurisdictions only loosely enforce their prohibition laws. Medical use is approved in 33 states.
Several states are expected to have some form of legalization referendums on their November ballots. And presumed Democratic presidential nominee Joe Biden this week said he would move to “decriminalize the use of cannabis and automatically expunge all prior cannabis use convictions.” It’s a step short of national legalization, but still a positive step for marijuana advocates.
Earnings Report
Investors will be looking for a revenue increase at Tilray, and hopefully a move toward profitability. The company said that it had a net loss of $0.62 per share and $46.94 million in revenue in the fourth quarter, compared with consensus estimates that called for a net loss of $0.35 per share and $55.38 million in revenue. The fourth-quarter net loss totaled $219.1 million.
“We generated net losses of $321.2 million, $67.7 million and $7.8 million for 2019, 2018 and 2017, respectively,” the company said in a 2019 SEC filing. “Our accumulated deficit was $430.1 million as of December 31, 2019.”
24/7 Wall St.
Is Cash the Only Savior for Aurora Cannabis Stock?
To cut costs, the company said in February that it was slashing 10% of its workforce. “By reducing headcount and cost, Tilray will be better positioned to achieve profitability and be one of the clear winners in the cannabis industry,” the company said in a statement.
Tilray is a diversified company, in the sense that it covers both recreational and medical cannabis, plus hemp. It also produces both THC and CBD products. Both are natural components found in marijuana, but only THC produces the emotional high associated with smoking marijuana recreationally. Marketers of CBD products tout the compound’s reported benefits for pain, anxiety and other conditions — all without a euphoric high.
Last year, revenues increased due to growth of the Canadian legal pot market and the completed acquisition of Manitoba Harvest. Manitoba sells hemp-based foods and supplements in 17,000 retail locations in 20 countries, including the U.S. and Canada. Analysts will be looking for an update on this retail play.
In the consumer space, look for news about THC and CBD edibles and beverages through Tilray’s High Park brand. Several products debuted in December, including Everie, a non-alcoholic CBD-infused drink produced by Fluent Beverages. Fluent is a joint venture between Tilray and AB InBev (NYSE: BUD). Drink marketers expect cannabis-infused drinks to be a growing trend.
https://247wallst.com/consumer-products ... ray-stock/
The stress of quarantine lockdown may be enough to drive a person to drink or drugs. Scientists are just starting to study whether drug use has gone up during the coronavirus pandemic.
So it’s too soon to tell what impact COVID-19 will have on legal and medical cannabis companies such as Canada’s Tilray Inc. (NASDAQ: TLRY). But analysts will be watching the company’s next earnings report, due May 11, for clues. Most expect marijuana stocks to remain volatile in the near term.
Tilray stock was up 5.23% in the last month, but is down over 57% year to date. This downward trend has attracted short sellers. And access to cash remains a concern.
Legalization Trends
As more U.S. states and foreign countries move to legalize recreational or medical cannabis products, legal investment options will grow. But nascent industries come with volatility. Tilray’s 52-week range spans from $2.43 to $51.03, with the stock currently trading in the $7 to $8 range.
Observers are closely watching the Canadian cannabis experiment. The country legalized recreational use in October 2018. Uruguay is the only other country to legalize the sale of recreational pot so far, though a few others have legalized its use.
Some cannabis industry executives actually think the current economic crisis could benefit them in the long run. They point out that alcohol prohibition ended quickly after the Great Depression, as the federal government badly needed revenue and job growth. Legalized marijuana taxes could be a tempting proposition for states (and maybe even Washington?) staring at empty coffers.
On the flip side, legalization efforts may be stymied by legislatures overwhelmed with other priorities. Grassroots efforts requiring the mass collection of voter signatures obviously face an uphill battle in the age of social distancing.
Recreational marijuana is currently legal in 11 states. A few other jurisdictions only loosely enforce their prohibition laws. Medical use is approved in 33 states.
Several states are expected to have some form of legalization referendums on their November ballots. And presumed Democratic presidential nominee Joe Biden this week said he would move to “decriminalize the use of cannabis and automatically expunge all prior cannabis use convictions.” It’s a step short of national legalization, but still a positive step for marijuana advocates.
Earnings Report
Investors will be looking for a revenue increase at Tilray, and hopefully a move toward profitability. The company said that it had a net loss of $0.62 per share and $46.94 million in revenue in the fourth quarter, compared with consensus estimates that called for a net loss of $0.35 per share and $55.38 million in revenue. The fourth-quarter net loss totaled $219.1 million.
“We generated net losses of $321.2 million, $67.7 million and $7.8 million for 2019, 2018 and 2017, respectively,” the company said in a 2019 SEC filing. “Our accumulated deficit was $430.1 million as of December 31, 2019.”
24/7 Wall St.
Is Cash the Only Savior for Aurora Cannabis Stock?
To cut costs, the company said in February that it was slashing 10% of its workforce. “By reducing headcount and cost, Tilray will be better positioned to achieve profitability and be one of the clear winners in the cannabis industry,” the company said in a statement.
Tilray is a diversified company, in the sense that it covers both recreational and medical cannabis, plus hemp. It also produces both THC and CBD products. Both are natural components found in marijuana, but only THC produces the emotional high associated with smoking marijuana recreationally. Marketers of CBD products tout the compound’s reported benefits for pain, anxiety and other conditions — all without a euphoric high.
Last year, revenues increased due to growth of the Canadian legal pot market and the completed acquisition of Manitoba Harvest. Manitoba sells hemp-based foods and supplements in 17,000 retail locations in 20 countries, including the U.S. and Canada. Analysts will be looking for an update on this retail play.
In the consumer space, look for news about THC and CBD edibles and beverages through Tilray’s High Park brand. Several products debuted in December, including Everie, a non-alcoholic CBD-infused drink produced by Fluent Beverages. Fluent is a joint venture between Tilray and AB InBev (NYSE: BUD). Drink marketers expect cannabis-infused drinks to be a growing trend.
https://247wallst.com/consumer-products ... ray-stock/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Is Tilray Stock A Buy Right Now? Here's What Earnings, Charts Show
https://www.investors.com/tilray-stock-buy-now/
https://www.investors.com/tilray-stock-buy-now/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray Earnings Report
Estimates: Wall Street expects Tilray to lose 27 cents per share. Revenue was expected to climb 21% to $55.32 million.
Results: Coming after the close.
Tilray stock climbed 4%. The stock has a 10 Composite Rating and a worst-possible 1 EPS Rating.
Before the earnings, Stifel analyst Andrew Carter called the quarter a "make or break" one for Tilray. And he called Tilray's forecasts for hitting positive EBITDA — or earnings before interest, taxes, depreciation and amortization —by the fourth quarter "aggressive," especially as the economy thrashes under the pandemic.
Getting a clear read on the medical marijuana markets abroad, he said, would be difficult, as industries in those nations come to life more slowly. In Canada, Carter said, consumption of Tilray's marijuana brands has been "tepid."
Estimates: Wall Street expects Tilray to lose 27 cents per share. Revenue was expected to climb 21% to $55.32 million.
Results: Coming after the close.
Tilray stock climbed 4%. The stock has a 10 Composite Rating and a worst-possible 1 EPS Rating.
Before the earnings, Stifel analyst Andrew Carter called the quarter a "make or break" one for Tilray. And he called Tilray's forecasts for hitting positive EBITDA — or earnings before interest, taxes, depreciation and amortization —by the fourth quarter "aggressive," especially as the economy thrashes under the pandemic.
Getting a clear read on the medical marijuana markets abroad, he said, would be difficult, as industries in those nations come to life more slowly. In Canada, Carter said, consumption of Tilray's marijuana brands has been "tepid."
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Wyniki Tirlay. Branża konopii w głębokiej zapaści?
W poniedziałek po zamknięciu notowań, raport kwartalny opublikował jeden z najważniejszych producentów marihuany. Tilray (TLRY 2,84%) ma w zwyczaju rozczarowywać wynikami i tym razem nie było inaczej. W jakiej kondycji jest doniczkowy biznes?
Raport Tilray nie pozostawia wątpliwości, że nie jest dobrze. W drugim kwartale spółka odnotowała przychody 50,4 mln USD, o około 10% wyższe niż w poprzednim kwartale (szacowano około 55,0 miliona USD), jednak największy niepokój budzą olbrzymie straty rzędu 0,65 USD na akcję (co nominalnie daje 81,7 miliona USD), to niemal dwukrotnie więcej niż kwartał temu i znacznie powyżej prognoz analityków (0,20 USD na akcję). Nic dziwnego, że we wtorek inwestorzy sprzedawali akcje.
Chociaż straty finansowe w zielonej branży nie są niczym zaskakującym, to wysoki deficyt wykazany przez - jakby nie patrzeć - jednego z największych producentów na rybku, każe zadać pytanie, co w biznesie nie działa. Tym bardziej, że lokalny konkurent Canopy Growth (CGC -0,75%), publikując wyniki kwartale tego samego dnia, wykazał wzrost przychodów o 22% r/r do 82,7 miliona USD i 0,30 USD na akcję straty netto, co zostało przyjęte przez inwestorów z zadowoleniem.
Kanadyjski hodowca, poza działalnością produkcyjną, prowadzi szereg działań w ranach ambitnego promowania publicznej legitymacji marihuany, angażując się w liczne badania kliniczne nad medycznym zastosowaniem zielonej roślinki. Ma to w przyszłości przynieść efekt, gdy legalizacje będą kontynuowane i rynek się odblokuje. Jednak czy przy niewielkich rocznych przychodach rzędu 175 milionów USD, bardzo dalekiej wizji rentowności i rosnącym zadłużeniem, plan Tirlay w ogóle ma szansę dojść do skutku? Obecnie firma musi zmagać się z krótkoterminowym planem restrukturyzacji, polegającym na ustabilizowaniu problemów z przepływami pieniężnymi, zamknięciem jednej plantacji i redukcji etatów. A i tak nie wiadomo, na ile przyniesie to efekt w dłuższym terminie.
Innymi słowy, chociaż Tilray i inne firmy rosną niczym chwasty w doniczkach, wykazują chroniczny brak opłacalności. Plantacje Tilray'a i jemu podobnych będą paliły światło tak długo jak ktoś będzie chciał do tego dopłacać, ponieważ większość banków w USA czy Kanadzie nie oferuje finansowania dla firm konopowych. Stąd też szereg mniejszych firm boryka się z kłopotami finansowymi, rezerwy gotówki topnieją i nie jest pewne, czy przetrwają w dłuższym terminie.
Reasumując, choć kanadyjskie organy regulacyjne zniweczyły szansę dla kraju na bycie liderem w dziedzinie konopii indyjskich, a najbliższe wybory w Stanach Zjednoczonych raczej nie wyhamują postępującej powoli legalizacji, branża doniczkowa to nadal wysoce ryzykowny sektor z trudnym do określenia planem rozwoju, z uwagi na liczne regulacje.
https://www.paszport.ws//wyniki-tirlay- ... pa%C5%9Bci
W poniedziałek po zamknięciu notowań, raport kwartalny opublikował jeden z najważniejszych producentów marihuany. Tilray (TLRY 2,84%) ma w zwyczaju rozczarowywać wynikami i tym razem nie było inaczej. W jakiej kondycji jest doniczkowy biznes?
Raport Tilray nie pozostawia wątpliwości, że nie jest dobrze. W drugim kwartale spółka odnotowała przychody 50,4 mln USD, o około 10% wyższe niż w poprzednim kwartale (szacowano około 55,0 miliona USD), jednak największy niepokój budzą olbrzymie straty rzędu 0,65 USD na akcję (co nominalnie daje 81,7 miliona USD), to niemal dwukrotnie więcej niż kwartał temu i znacznie powyżej prognoz analityków (0,20 USD na akcję). Nic dziwnego, że we wtorek inwestorzy sprzedawali akcje.
Chociaż straty finansowe w zielonej branży nie są niczym zaskakującym, to wysoki deficyt wykazany przez - jakby nie patrzeć - jednego z największych producentów na rybku, każe zadać pytanie, co w biznesie nie działa. Tym bardziej, że lokalny konkurent Canopy Growth (CGC -0,75%), publikując wyniki kwartale tego samego dnia, wykazał wzrost przychodów o 22% r/r do 82,7 miliona USD i 0,30 USD na akcję straty netto, co zostało przyjęte przez inwestorów z zadowoleniem.
Kanadyjski hodowca, poza działalnością produkcyjną, prowadzi szereg działań w ranach ambitnego promowania publicznej legitymacji marihuany, angażując się w liczne badania kliniczne nad medycznym zastosowaniem zielonej roślinki. Ma to w przyszłości przynieść efekt, gdy legalizacje będą kontynuowane i rynek się odblokuje. Jednak czy przy niewielkich rocznych przychodach rzędu 175 milionów USD, bardzo dalekiej wizji rentowności i rosnącym zadłużeniem, plan Tirlay w ogóle ma szansę dojść do skutku? Obecnie firma musi zmagać się z krótkoterminowym planem restrukturyzacji, polegającym na ustabilizowaniu problemów z przepływami pieniężnymi, zamknięciem jednej plantacji i redukcji etatów. A i tak nie wiadomo, na ile przyniesie to efekt w dłuższym terminie.
Innymi słowy, chociaż Tilray i inne firmy rosną niczym chwasty w doniczkach, wykazują chroniczny brak opłacalności. Plantacje Tilray'a i jemu podobnych będą paliły światło tak długo jak ktoś będzie chciał do tego dopłacać, ponieważ większość banków w USA czy Kanadzie nie oferuje finansowania dla firm konopowych. Stąd też szereg mniejszych firm boryka się z kłopotami finansowymi, rezerwy gotówki topnieją i nie jest pewne, czy przetrwają w dłuższym terminie.
Reasumując, choć kanadyjskie organy regulacyjne zniweczyły szansę dla kraju na bycie liderem w dziedzinie konopii indyjskich, a najbliższe wybory w Stanach Zjednoczonych raczej nie wyhamują postępującej powoli legalizacji, branża doniczkowa to nadal wysoce ryzykowny sektor z trudnym do określenia planem rozwoju, z uwagi na liczne regulacje.
https://www.paszport.ws//wyniki-tirlay- ... pa%C5%9Bci
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Aphria, Tilray To Form Largest Cannabis Company By Sales In Merger
Aphria stock and Tilray stock surged Wednesday after announcing a merger that would create the biggest weed company by revenue. Other marijuana stocks also rose.
Under the deal, which was first reported by BNN Bloomberg Tuesday, Aphria (APHA)shareholders will receive 0.8381 shares of Tilray's (TLRY) for each Aphria stock they own. Aphria will own about 62% of the combined company.
The merged company will take the Tilray name and to trade under TLRY stock ticker.
While the combined equity value of about $3.9 billion will still be smaller than that of Canopy Growth's (CGC), Aphria and Tilray say their combined revenue of $685 million will create the world's largest cannabis company by that metric.
Aphria's current chairman and CEO, Irwin Simon, will take on those roles for the combined company. Tilray CEO Brendan Kennedy will be named to the board, along with another Tilray executive.
Aphria and Aurora Cannabis (ACB) were rumored to be in merger talks earlier in the year. The merger talks would come as Canada's pot industry looks for ways to lean down, after years of losses.
Aphria in November said it would enter the U.S. via an agreement to buy craft brewer Sweetwater Brewing Co. for around $300 million. SweetWater is known for beers that use terpenes and hemp flavoring. Aphria said the brand was "closely aligned with a cannabis lifestyle." Tilray owns Manitoba Harvest, a hemp company that sells products in the U.S. and Canada.
IBD Live: A New Tool For Daily Stock Market Analysis
Aphria, Tilray Lead Marijuana Stocks Higher
Aphria stock rallied 6.5% to 8.65 in premarket trading on the stock market today. Tilray jumped 27%. Canopy Growth added 1.7%. Cronos Group (CRON) was up 3.9%. Aurora Cannabis gained 1.7%.
President-elect Biden has said he supports federal marijuana decriminalization. This month, the U.S. House of Representatives voted to pass the MORE Act, which would remove marijuana from the list of controlled substances.
The bill, however, faces little chance in the Senate. Two runoff elections next month in Georgia will determine the balance of the Senate, and how much advantage the Democrats will have in passing cannabis reform.
New Jersey, Arizona, Montana and South Dakota on Election Day approved ballot measures to legalize recreational marijuana. South Dakotans and Mississippi voters also backed some degree of medical use.
https://www.investors.com/news/aphria-s ... ger-talks/
Powstanie największy na świecie diler marihuany
MAREK DRUŚ
opublikowano: dzisiaj, 17-12-2020, 06:18
Kanadyjskie Aphria Inc. i Tilray Inc. uzgodniły fuzję wartości 4,8 mld CAD (3,9 mld USD), której wynikiem będzie powstanie największego na świecie dilera marihuany.
Transakcja zostanie przeprowadzona w drodze wymiany akcji. Powstała spółka będzie miała ok. 874 mln CAD sprzedaży rocznej, czyli wyraźnie więcej niż najwięksi rywale, m.in. Curaleaf Holdings i Canopy Growth Corp.
https://www.pb.pl/powstanie-najwiekszy- ... ny-1103484
Aphria stock and Tilray stock surged Wednesday after announcing a merger that would create the biggest weed company by revenue. Other marijuana stocks also rose.
Under the deal, which was first reported by BNN Bloomberg Tuesday, Aphria (APHA)shareholders will receive 0.8381 shares of Tilray's (TLRY) for each Aphria stock they own. Aphria will own about 62% of the combined company.
The merged company will take the Tilray name and to trade under TLRY stock ticker.
While the combined equity value of about $3.9 billion will still be smaller than that of Canopy Growth's (CGC), Aphria and Tilray say their combined revenue of $685 million will create the world's largest cannabis company by that metric.
Aphria's current chairman and CEO, Irwin Simon, will take on those roles for the combined company. Tilray CEO Brendan Kennedy will be named to the board, along with another Tilray executive.
Aphria and Aurora Cannabis (ACB) were rumored to be in merger talks earlier in the year. The merger talks would come as Canada's pot industry looks for ways to lean down, after years of losses.
Aphria in November said it would enter the U.S. via an agreement to buy craft brewer Sweetwater Brewing Co. for around $300 million. SweetWater is known for beers that use terpenes and hemp flavoring. Aphria said the brand was "closely aligned with a cannabis lifestyle." Tilray owns Manitoba Harvest, a hemp company that sells products in the U.S. and Canada.
IBD Live: A New Tool For Daily Stock Market Analysis
Aphria, Tilray Lead Marijuana Stocks Higher
Aphria stock rallied 6.5% to 8.65 in premarket trading on the stock market today. Tilray jumped 27%. Canopy Growth added 1.7%. Cronos Group (CRON) was up 3.9%. Aurora Cannabis gained 1.7%.
President-elect Biden has said he supports federal marijuana decriminalization. This month, the U.S. House of Representatives voted to pass the MORE Act, which would remove marijuana from the list of controlled substances.
The bill, however, faces little chance in the Senate. Two runoff elections next month in Georgia will determine the balance of the Senate, and how much advantage the Democrats will have in passing cannabis reform.
New Jersey, Arizona, Montana and South Dakota on Election Day approved ballot measures to legalize recreational marijuana. South Dakotans and Mississippi voters also backed some degree of medical use.
https://www.investors.com/news/aphria-s ... ger-talks/
Powstanie największy na świecie diler marihuany
MAREK DRUŚ
opublikowano: dzisiaj, 17-12-2020, 06:18
Kanadyjskie Aphria Inc. i Tilray Inc. uzgodniły fuzję wartości 4,8 mld CAD (3,9 mld USD), której wynikiem będzie powstanie największego na świecie dilera marihuany.
Transakcja zostanie przeprowadzona w drodze wymiany akcji. Powstała spółka będzie miała ok. 874 mln CAD sprzedaży rocznej, czyli wyraźnie więcej niż najwięksi rywale, m.in. Curaleaf Holdings i Canopy Growth Corp.
https://www.pb.pl/powstanie-najwiekszy- ... ny-1103484
Ostatnio zmieniony 21 lut 2021 01:50 przez slayer74, łącznie zmieniany 1 raz.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray TLRY reported Q4 results that beat some expectations,and the Canadian cannabis producer became the rare weed company to deliver on its profitability goals.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray (TLRY), a Canadian cannabis producer, reported fi rst quarter results that missed expectations.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Tilray NASDAQ: TLRY produkcja medycznej marihuany
Tilray (NASDAQ:TLRY) stock soared 18%, with cannabis stocks benefiting from the news that the House of Representatives will consider the Marijuana Opportunity Reinvestment and Expungement Act next week.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 11 gości